Background
==========

Amino acid transporters are essential for a variety of physiological cellular processes, including uptake of nutrients, energy and chemical metabolism, as well as malignant transformation \[[@B1]\]. Amino acid transporters include system A (ATA1/SNAT1/SLC38A1, ATA2/SNAT2/SLC38A2 and ATA3/SNAT4/SLC38A4), system L (LAT1/SLC7A5 and LAT2/SLC7A8), and y + (CAT2/SLC7A2). Among the various amino acid transporters, system L-type amino acid transporter-1 (LAT-1) is up-regulated in a wide variety of human cancers, including esophageal adenocarcinoma \[[@B2]\], oral squamous cell carcinoma \[[@B3]\], colorectal adenocarcinoma \[[@B4]\], and liver cancer \[[@B5]\]. System A amino acid transporter is also overexpressed in human cancers \[[@B5]-[@B8]\]. System A is a Na^+^-dependent active transport system, known to mediate the uptake of amino acids with small side chains (e.g., alanine, serine, proline and glutamine) \[[@B1]\]. Its activity is highly influenced by pH, cell volume, and a variety of hormones, such as insulin, glucagon, and insulin-like growth factor-I \[[@B1]\].

System A transporter in mammalian cells includes three distinct types, known as amino acid transporters SLC38A1, SLC38A2 and SLC38A4 \[[@B9]\]. These transporters belong to the solute-linked carrier family SLC38, and are differentially expressed among different organs/tissues. SLC38A1 is expressed primarily in the brain and placenta, as opposed to the lungs, liver, spleen and kidneys \[[@B10]\]. SLC38A2 is, on the other hand, ubiquitously expressed in mammalian tissues \[[@B9]\], while SLC38A4 is primarily expressed in the liver \[[@B11]\]. System A transporters are up-regulated in a range of human cancers, including breast cancer and hepatocellular cancer \[[@B6],[@B7]\].

Our previous studies, using gene chip analysis, suggested elevated SLC38A1 mRNA expression in gastric cancer (unpublished data). In the current study, we compared the expression of SLC38A1 in gastric carcinoma in contrast with healthy adjacent gastric mucosa at the protein level. Potential correlation of SLC38A1 with the prognosis was examined using a multivariate analysis, and the biological role of SLC38A1 in proliferation and progression was examined in cultured gastric cancer cells using siRNA.

Methods
=======

Patients
--------

This study included 896 patients (median age: 61.4 years; 634 men, 262 women) with histologically confirmed gastric cancer who underwent D2/D3 curative resection at either Changhai or Changzheng Hospital in Shanghai, during a period from 2001 to 2005. Subjects who received neo-adjuvant therapy prior to the surgery were not included. Subjects with stage III disease also received a 5-fluorouracil-based chemotherapeutic regimen for 4--6 cycles. Patients presenting with neuroendocrine tumors, lymphoma or sarcoma were not included. Adjacent mucosa that was free from cancer cells was used as a healthy control.

The follow-up was conducted via phone conversation and mail in March 2010. Information with regards to survival/death was obtained in 673 cases (median survival: 59.08 months).

Demographic information and the construction of TMA blocks were described previously \[[@B12]-[@B15]\]. All tissue specimens were obtained with informed consent, and the use of the human specimens was approved by Institutional Review Board at Changhai and Changzheng Hospitals.

Immunohistochemistry (IHC)
--------------------------

Immunohistochemical staining was carried out on 4-μm paraffin sections after heat-mediated antigen retrieval. Samples were incubated with a human-anti-rabbit polyclonal antibody to SLC38A1 (dilution 1:200; Abcam, Cambridge, U K) overnight at 4°C. Goat anti-rabbit antibody (dilution 1:4000; Invitrogen, Carlsbad, CA, USA) was used as a secondary antibody. An immunoglobulin-negative control was used to rule out non-specific binding. As for the positive control, we referred to other studies in liver cells by Nobuo Kondoh \[[@B6]\] and in hilar cholangiocarcinoma by Yu WL \[[@B16]\], which indicated the SLC38A1 protein was stained brown and diffused in the cytoplasm. Slides were counterstained with hematoxylin.

Data (staining in cytoplasma) were acquired independently by two investigators (Guan Zhen Yu and Ying Chen) blinded to sample nature using an Olympus CX31 microscope (Olympus, Center Valley, PA, USA), and analyzed using a semi-quantitative scoring system. Staining was graded on a scale of 0--2 (0 = negative staining \[no cytoplasmic staining of any tumor cells\], 1 = moderate expression \[cytoplasmic staining of \<25% of tumor cells\], and 2 = high expression \[cytoplasmic staining of ≥25% of tumor cells\]) as described previously \[[@B14],[@B17]\].

Cell culture and siRNA transfection
-----------------------------------

SH-10-TC cells were obtained from Shanghai Institute for Biological Sciences, Chinese Academy of Sciences (CAS), and grown in RPMI-1640 medium containing 10% FBS. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO~2~. The experiments were carried out in the exponential phase of growth.

Four pairs of anti-SLC38A1 siRNAs and randomized cocktails of dsRNA as a control were synthesized by GenePharma (Shanghai, China). The siRNA transfection was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).

Western blot analysis
---------------------

Cell lysate containing 100 μg protein was resolved on SDS-PAGE, transferred onto PVDF membrane and incubated with an anti-SLC38A1 antibody (dilution, 1:500; Invitrogen, Carlsbad, CA, USA). Protein bands were evaluated using an Odyssey infrared fluorescent scanning system (LI-COR Biosciences, Lincoln, NE, USA) and Scion Image software (NIH, USA). GAPDH was used as an internal control.

Cell viability
--------------

SH-10-TC cells were seeded in 96-well plates at the day before transfection. Cells were counted at 48 h, 72 h and 96 h after transfection using a microtiter-plate colorimetric WST assay (Cell counting kit-8; Dojindo Laboratories, Kumamoto, Japan) at 450 nm. Experiments were conducted in triplicate.

Transwell migration and invasion assay
--------------------------------------

Assays were performed using a modified Boyden chamber (Corning Costar, Rochester, NY, USA) containing a gelatin-coated polycarbonate membrane filter (8-μm pore size). The upper surface of the filter was coated with 20 μL Matrigel (0.3 mg/ml; BD Biosciences, Bedford, MA, USA). Transfected cells were harvested with a cell dissociation solution (Invitrogen, Carlsbad, CA, USA) and suspended in medium with 1% bovine serum albumin.

Cells (1 × 10^4^) were added to the upper compartment and allowed to migrate for 6 h at 37°C. After 6 h, cells on the upper side of the membrane were removed with a cotton swab. Cells on the bottom surface of the membrane were fixed in 3.7% paraformaldehyde, stained with hematoxylin for quantification. Data were expressed as the average number of cells per insert.

Statistical analysis
--------------------

The relationship between SLC38A1 expression and clinicopathologic parameters was analyzed using the chi-square test. Survival was analyzed using the Kaplan-Meier method and the log-rank test. The prognostic value of clinicopathologic parameters was examined using a Cox proportional hazards regression model for multivariate analysis. All tests were two-sided. *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS statistical software program for Microsoft Windows (SPSS Inc., Chicago, IL, USA).

Results
=======

SLC38A1 protein in gastric cancer
---------------------------------

The expression of SLC38A1 protein in the healthy gastric mucosa was very low or undetectable (Figure  [1](#F1){ref-type="fig"}A). Strong staining of SLC38A1 protein in the cytoplasm was found in 495 out of the 896 cancer samples in both the well differentiated (Figure  [1](#F1){ref-type="fig"}B), and poorly differentiated cancer cells (Figure  [1](#F1){ref-type="fig"}C). In the cytoplasm, the SLC38A1 protein was stained brown and diffused.

![**Human gastric cancers and healthy mucosa specimens in tissue microarray were stained with an anti-SLC38A1. (A)** Representative healthy gastric tissue without SLC38A1 cytoplasmic expression, **(B)** Well-differentiated and **(C)** Morderately-differentiated gastric cancer tissues with positive SLC38A1 expression which was cytoplasm stained brown and diffuse. Magnification × 200.](1471-230X-14-70-1){#F1}

SLC38A1 expression and clinicopathologic factors
------------------------------------------------

SLC38A1 overexpression was closely associated with old age (\>60 yrs), differentiation status (high/moderate), regional lymph node metastasis, TNM stage (III), and positive PCNA expression (Table  [1](#T1){ref-type="table"}), but not with gender, tumor size, tumor location, operation manner, lymphovascular invasion, depth of tumor invasion, and p53 expression.

###### 

Association between SLC38A1 expression and clinicopathological factors of GC patients

  **Clinicopathological variables**    **Total**   **SLC38A1 positive expression**  
  ----------------------------------- ----------- --------------------------------- ---------
  Age                                                                                 0.007
  ≤ 60 years                              447                    227                     
  \> 60 years                             449                    268                     
  Sex                                                                                 0.437
  Male                                    634                    345                     
  Female                                  262                    150                     
  Location                                                                            0.277
  Cardia                                  144                    86                      
  Corpus                                  281                    150                     
  Antrum                                  440                    246                     
  Whole                                   31                     13                      
  Operation manner                                                                    0.590
  Subtotal gastrectomy                    400                    217                     
  Total gastrectomy                       496                    278                     
  Size (Diameter)                                                                     0.321
  ≤ 6 cm                                  706                    384                     
  \> 6 cm                                 190                    111                     
  Differentiation                                                                    \<0.001
  High/moderate                           553                    337                     
  Low/undifferentiated                    343                    158                     
  Gastric wall invasion                                                               0.151
  T1/T2                                   308                    160                     
  T3/T4                                   588                    335                     
  lymph node metastasis                                                               0.026
  Negative                                346                    175                     
  Positive                                550                    320                     
  TNM stage                                                                           0.001
  I/II                                    427                    212                     
  III                                     469                    283                     
  Lymphovascular invasion                                                             0.275
  Negative                                850                    466                     
  Positive                                46                     29                      
  p53 expression                                                                      0.382
  Negative                                401                    228                     
  Positive                                495                    267                     
  PCNA expression                                                                     0.012
  Negative                                99                     43                      
  Positive                                797                    452                     

Prognostic factors of overall survival
--------------------------------------

SLC38A1 expression in cancer tissue was associated with poorer prognosis. The median survival was 46.69 months in patients with SLC38A1-positive cancers, and 69.7 months in subjects with SLC38A1-negative cancers (*P* = 0.002; Figure  [2](#F2){ref-type="fig"}). Upon a multivariate analysis, independent prognostic factors for overall survival included SLC38A1 expression, differentiation status, lymphovascular invasion, PCNA expression, size and TNM stage (Table  [2](#T2){ref-type="table"}).

![**Association between SLC38A1 expression and survival duration in patients with gastric cancer.** Kaplan-Meier survival analysis showed median survival of 46.69*vs.*69.7 months in patients with positive vs. negative SLC38A1 expression (*P* = 0.002).](1471-230X-14-70-2){#F2}

###### 

Univariate and multivariate analysis of the prognostic significance of individual clinicopathological factors on survival

                                                              **Univariate analysis**   **Multivariate analysis**                                          
  ---------------------------------------------------------- ------------------------- --------------------------- ------- ------- ------- ------- ------- ------
  Size (≤ 6 cm vs. \> 6 cm)                                            1.816                      1.429             2.309   .000    1.327   1.039   1.696   .024
  TNM (I/II vs. III)                                                   4.214                      3.292             5.393   .000    3.416   2.637   4.424   .000
  Differentiation (high/moderate vs. low/undifferentiated)             1.876                      1.509             2.332   .000    1.565   1.249   1.960   .000
  Nerve invasion (negative vs. positive)                               2.070                      1.421             3.015   .000    1.353   .910    2.011   .135
  Lymphovascular invasion (negative vs. positive)                      2.664                      1.770             4.011   .000    1.931   1.258   2.964   .003
  PCNA (negative vs. positive)                                         1.794                      1.174             2.742   0.007   1.695   1.098   2.617   .017
  P53 (negative vs. positive)                                          1.277                      1.024             1.593   0.03    1.046   .835    1.310   .695
  SLC38A1 (negative vs. positive)                                      1.191                      1.065             1.332   0.002   1.122   1.001   1.258   .041

RNAi experiments
----------------

Specific knockdown of endogenous SLC38A1 protein was confirmed by all four siRNAs with Western blot (Figure  [3](#F3){ref-type="fig"}A). siRNA \#2 (si-SLC38A1) reduced the endogenous SLC38A1 transcript by \>70%, and was selected for subsequent experiments.

![**Silencing SLC38A1 with siRNA in SH-10-TC cells and experiments in vitro. (A)** Representative Western blot in the siRNA experiments. siRNA \#2 reduced the SLC38A1 transcript by \>70% in comparison to scrambled control (lane1 and 6). GAPDH was used as the internal control. **(B)** CCK-8 assay shows si-SLC38A1 significantly inhibited the cell growth of SH-10-TC cells. **(C)** Upper panel: si-SLC38A1 decreased the migration of SH-10-TC cells in transwell chambers, compared to parental cells and si-Ctl group. Lower panel: migrated cells on the surface of the membrane (Columns, mean; bars, SD. \*, *P* \< 0.01 vs. scrambled control).](1471-230X-14-70-3){#F3}

Compared to parental cells and si-Ctl, si-SLC38A1 decreased the proliferation (Figure  [3](#F3){ref-type="fig"}B), as well as the migration of SH-10-TC cells (Figure  [3](#F3){ref-type="fig"}C), but did not affect cell passage through Matrigel.

Discussion
==========

Consistent with the physiological and pathological roles of glutamate in cancer development, we found marked differences in the expression of SLC38A1 in gastric cancer relative to adjacent non-cancerous tissue. The uncontrolled proliferation of neoplastic cells requires dramatic changes in energy metabolism \[[@B18]\], in which the primary metabolic fuel and nitrogen source for tumor cells in glutamine \[[@B19]-[@B21]\]. Glutamine is known to exert influence on a number of signaling pathways that contribute to tumor growth \[[@B22]\], and is additionally correlated with maintaining the TCA cycle and supporting NADPH production when glucose supply is limited \[[@B23]\].

While glutamine is not an essential amino acid, it plays an important role in maintaining the intestinal barrier structure and immune function. Within the three mammalian system A amino acid transporters, SLC38A1 has the highest affinity for glutamine, and is strongly expressed in glutamatergic neurons \[[@B24]\].

Low blood glutamine concentration has been found in patients with gastric carcinoma and conversely increased in the mucous membrane adjacent to the malignant tissue \[[@B25]\]. It is possible that ectopic activation of SLC38A1 may reflect a compensatory mechanism that confers a survival advantage.

SLC38A1 expression in gastric cancer and other malignancies
-----------------------------------------------------------

In the present study, we found an increased expression of SLC38A1 in gastric carcinomas, relative to adjacent non-cancerous gastric mucosa, suggesting that SLC38A1 might play an important part in gastric cancer malignant transformation. Enhanced SLC38A1 expression has been observed in several other types of malignancies, including liver cancer \[[@B6]\], Hilar cholangiocarcinoma \[[@B16]\] and C6 glioma \[[@B26]\]. An elevated expression of SLC38A1 has been found to be closely linked to differentiation status, lymph node metastasis and TNM staging, and is thus implicated in the growth, invasion, metastasis and progression of gastric carcinomas.

Potential mechanism of the action
---------------------------------

Consistent with the observation in HepG2 liver cancer cell lines \[[@B6]\], our study showed that inhibiting SLC38A1 expression with siRNA decreased the growth of cultured SH-10-TC cells, thus indicating an overexpression of SLC38A1 contributes to oncogenesis of gastric cancer through promoting cell proliferation. Inhibiting SLC38A1 expression also reduced cell migration, providing evidence for increased cell migration as a mechanism for enhanced metastatic potential, and local invasiveness of SLC38A1-expressing tumor cells.

In breast cancer, scientists discovered that 17 beta-estradiol specifically increased System A activity by two to four-fold in estrogen receptor positive cell lines, with a maximum stimulation observed 48 h after estrogen-treatment. In estrogen receptor negative cell lines, however, no stimulation was observed, which provided evidence that estrogen receptors play a role in the activation of system A by estrogen \[[@B27]\]. In liver cancer, System A amino acid transporters produced a different kind of inactivation and substrate protection in membrane vesicles and reconstituted proteoliposomes, supporting the hypothesis that there were inherent differences presented in System A carriers in normal and transformed liver tissue \[[@B28]\]. In the current study, we found enhanced SCL38A1 expression in gastric cancer, which supported the implication of glutamine metabolism in tumors \[[@B29]-[@B31]\]. Interestingly, certain cancer cell lines are dependent on glutamine despite the fact that glutamine is a nonessential amino acid \[[@B32]\]. To be utilized by tumor cells, glutamine must be transported into tumor cell mitochondria. This implies that SLC38A1 could transport glutamine, and thus play an important role in neoplastic progression/development.

Association of SLC38A1 expression with clinicopathological characteristics as well as prognosis in patients with GC
-------------------------------------------------------------------------------------------------------------------

Upon further investigation of the relationship between SLC38A1 and clinicopathological factors, we found that overexpression of SLC38A1 was strongly associated with patient age, differentiation status, lymph node metastasis, TNM stage and the expression of PCNA, whereas no significant association was found in patient gender, tumor size, tumor location, operation manner, lymphovascular invasion, depth of tumor invasion, and p53 expression. These results indicated that SLC38A1 plays a central role in the malignant progression of gastric carcinomas.

Risk factors for gastric cancers have been reported in a number of studies, including differentiation, \[[@B33]\] nerve invasion \[[@B33]\], lymphovascular invasion \[[@B33]\], size \[[@B13],[@B34]\], TNM stage \[[@B34]\], and some molecular markers \[[@B35]\]. Our study confirmed that differentiation, lymphovascular invasion and the TNM stage were independent predictors for gastric cancer. We additionally found that SLC38A1 expression alone was a prognostic factor, with its prognostic value in multivariate survival analysis for patients who underwent gastrectomy. Therefore, we supposed that overexpression of SLC38A1 is a significant factor associated with a poor prognosis, and might be a marker to forecast gastric cancer patients' recurrence and survival. Secondly, patients with poorer prognosis should be monitored more closely and/or undergo more positive treatment.

Conclusion
==========

In conclusion, our study showed that SLC38A1 expression was closely associated with age, differentiation status, lymph node metastasis, TNM stage and PCNA expression, as well as a worse prognosis in patients with gastric cancer. The results from the experiments using cultured gastric cancer cells indicated that SLC38A1 expression could be used as an indicator of disease aggressiveness. Overall, these findings could be useful in developing a novel molecular target for individualized treatment of gastric cancer.
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